What's Next for DCTs?
No longer "down the road" in their emergence, this issue of Applied Clinical Trials takes a deep look at the impact of decentralized clinical trials to date—and how their future trajectory could shape out.
One of the most prominent areas of discussion in our industry since the COVID-19 pandemic has been decentralized clinical trials (DCTs). While discourse certainly peaked during that time, I find that the conversations around DCTs in the present are a bit different. During COVID, DCTs were leading a number of advancements we thought were years down the road. Now that we are “years down the road,” a lot of the talk around DCTs involves the key question of, “What’s next?” DCTs are still an incredible tool for studies, but we now need to find ways to sustain that. This July/August issue of Applied Clinical Trials takes a hard look into the current state of DCTs and what their future could look like.
Our coverage begins with a special feature on the overarching theme of evaluating the
Our second
For additional insights into the world of DCTs, this issue also includes a
On a side note, in June, ACT was present at one of the forefront events in drug development every year—the Drug Information Association’s Global Annual Meeting. For full coverage, please visit our website conference page
As always, thank you for reading.
Mike Hennessy Jr is president and CEO of MJH Life Sciences®
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.